Testing ONO-4685 for T cell lymphoma and CLL/SLL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug, ONO-4685, for people with certain types of T cell lymphoma or chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) that has not responded to standard treatments or cannot tolerate them. The goal is to see if the drug is safe and tolerable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of one of these: peripheral T cell lymphoma, angioimmunoblastic T cell lymphoma, cutaneous T cell lymphoma, mycosis fungoides, Sezary syndrome, or CLL/SLL.
- Your cancer has come back after treatment or has not responded to standard therapies, and no standard treatment is available or you cannot take it.
- You are able to perform daily activities with minimal help (ECOG performance score of 0 to 2).
- Your doctor expects you to live at least 3 more months.
- You do not have severe medical complications or other active cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (ONO-4538) for people with Richter's transformation, a rare and aggressive lymphoma that can happen to people with CLL or SLL. It aims to see if the drug can help when standard treatments have stopped working or aren't an option.
This early-phase (Phase 1) study tests ONO-4685 in adults whose T-cell lymphoma has come back or did not respond to treatment. It aims to find a safe dose and see whether it can shrink lymphoma in people with limited options.
This trial is testing several new drug combinations for people with peripheral T-cell lymphoma that has come back or not responded to treatment. It aims to find new options that may work better.
This trial tests a new drug called golidocitinib added to standard chemotherapy (CHOP) for people newly diagnosed with certain types of T-cell lymphoma. It aims to see if the combination works better than CHOP alone.
This trial tests a new treatment called TORL-5-700 for people with certain types of non-Hodgkin lymphoma that have not responded to other treatments. The goal is to see how safe it is and how well it works.
This trial tests an experimental drug called NX-5948 for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to prior treatments. It's for those who have already tried a BTK inhibitor and a BCL-2 inhibitor.
Hear when a new Relapsed or Refractory T Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.